FREQUENTLY ASKED QUESTIONS

FIND ANSWERS YOU’RE LOOKING FOR

We’ll send a local representative to your practice to talk more about TEZSPIRE.

REQUEST A REP 

According to an analysis of patients in the International Severe Asthma Registry, approximately 2 out of 3 patients have multiple drivers activated.1*

*Data from the International Severe Asthma Registry (ISAR), a global initiative to gather anonymous, longitudinal real-life data. Patients with severe asthma enrolled in ISAR are ≥18 years of age and either have uncontrolled asthma at Global Initiative for Asthma (GINA) step 4 treatment or are receiving GINA step 5 treatment; all were on high-dose inhaled corticosteroids. Data were analyzed from 1175 patients from 10 countries in North America, Europe, and Asia, with prespecified thresholds for biomarker positivity (total serum IgE ≥75 kU/L, blood eosinophils ≥300 cells/μL, and FeNO ≥25 ppb). In this study, 59% of patients were positive for 2 or 3 of biomarkers assessed.1

FeNO=fractional exhaled nitric oxide; IgE=immunoglobulin E; ppb=parts per billion.

SEE MORE ON ASTHMA DRIVERS 

A variety of publications show multiple triggers and drivers can lead to clinical manifestations, such as exacerbations, mucus production, reduced quality of life, and reduced lung function.2-5

SEE MORE ON ASTHMA DRIVERS

When triggers make contact with the epithelium, it can cause the release of TSLP, which can result in the activation of multiple drivers, such as IL-5 (blood EOS), IL-4 (IgE), IL-13 (FeNO), and mast cells (AHR). This downstream inflammation can lead to clinical manifestations, including exacerbations, mucus production, reduced quality of life, and reduced lung function.3-6

TEZSPIRE blocks TSLP at a source of inflammation to help prevent activation of multiple drivers.3-6

The mechanism of action of TEZSPIRE in asthma has not been definitively established. Definitive conclusions cannot be made.

AHR=airway hyperresponsiveness; EOS=eosinophils; FeNO=fractional exhaled nitric oxide; IgE=immunoglobulin E; IL=interleukin; TSLP=thymic stromal lymphopoietin.

SEE MECHANISM OF ACTION

In CASCADE,* a phase 2 study, blocking TSLP with TEZSPIRE impacted airway hyperresponsiveness.7

  • TEZSPIRE + SOC showed a 197.4 mg change from baseline in PD15† of mannitol vs 58.6 mg with placebo + SOC‡

Increase in the PD15 of mannitol indicates reduced airway hyperresponsiveness.7

Results are descriptive only. The mechanism of action of TEZSPIRE and the clinical significance of these outcomes and their impact on asthma have not been established.

*In CASCADE, the primary endpoint was the change, expressed as a ratio, from baseline to EOT in the number of airway submucosal cells per mm2 in bronchoscopic biopsy samples. Airway submucosal eosinophils (LS mean ratio of cell count at EOT vs baseline) with TEZSPIRE + SOC (n=48) was 0.11 (95% CI: 0.05-0.24) and with placebo + SOC (n=51) was 0.75 (95% CI: 0.37-1.55).7

†PD15 is defined as the cumulative provoking dose (PD) of mannitol required to induce ≥15% reduction in FEV1 from baseline zero mannitol dose (PD15), or otherwise ≥10% reduction in FEV1 between successive nonzero mannitol doses.7,8

‡In CASCADE, airway hyperresponsiveness to mannitol was reduced in patients treated with TEZSPIRE + SOC vs placebo + SOC at EOT. LS mean change from baseline in interpolated or extrapolated absolute PD15 of mannitol (TEZSPIRE [n=24] 197.4 mg [95% CI: 107.9-286.9]; placebo [n=24] 58.6 mg [95% CI: -30.1 to 147.33]) and in doubling doses of PD15 to mannitol (TEZSPIRE [n=24] 1.41 [95% CI: 0.84-1.99]; placebo [n=24] 0.57 [95% CI: 0.01-1.13]; difference 0.84 [95% CI: 0.04-1.65]).7,8

AHR=airway hyperresponsiveness; CI=confidence interval; EOT=end of treatment; FEV1=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care; TSLP=thymic stromal lymphopoietin.

SEE IMPACT ON AHR

TEZSPIRE is contraindicated in patients with a known hypersensitivity to tezepelumab or its excipients. Hypersensitivity reactions, including rash, allergic conjunctivitis, and anaphylaxis can happen. These generally occur within hours of administration but can have a delayed onset. Consider the benefits and risks.

Do not abruptly discontinue corticosteroids. Dose reductions, if appropriate, should be gradual and may be associated with withdrawal symptoms and/or unmask previously controlled conditions. Treat patients with pre-existing helminth infections before starting TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until the infection resolves. Avoid use of live attenuated vaccines.

In an overall population, TEZSPIRE showed significant exacerbation reductions versus placebo (PATHWAY 71%, NAVIGATOR 56%, P<0.001; primary endpoint) and a 230 mL improvement in lung function versus baseline (NAVIGATOR; secondary endpoint).6*

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% CI: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% CI: 0.37-0.53).6

AAER=annualized asthma exacerbation rate; CI=confidence interval; RR=rate ratio; SOC=standard of care.

EXPLORE EFFICACY

In an overall population, TEZSPIRE showed significant exacerbation reductions versus placebo (PATHWAY 71%, NAVIGATOR 56%, P<0.001; primary endpoint) and a 230 mL improvement in lung function versus baseline (NAVIGATOR; secondary endpoint).6† In a post hoc analysis of patients with EOS 150-299 cells/μL with positive aeroallergen testing,* the following data were observed with TEZSPIRE9:

  • 77% reduction in exacerbations from baseline‡§ (TEZSPIRE + SOC [n=137]; baseline 2.60 vs EOT 0.60)
  • 96% reduction in exacerbations requiring hospitalizations, urgent care, or ED visits from baseline‡II (TEZSPIRE + SOC [n=137]; baseline 0.47 vs EOT 0.02)
  • 120 mL improvement in FEV1 from baseline (TEZSPIRE + SOC [n=134])

Results are descriptive only. Definitive conclusions cannot be made.

*Allergic status as defined by a serum IgE result specific to any perennial aeroallergen in the FEIA panel.9

†PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% CI: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% CI: 0.37-0.53).6

‡Baseline is defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT is defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).9

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.42 and EOT 1.28 (n=132; 47% reduction from baseline).9‡

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.33 and EOT 0.11 (n=132; 67% reduction from baseline).9‡

Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 100 mL (n=132); LS mean difference between groups 20 mL (95% CI: -70 to 120).9

AAER=annualized asthma exacerbation rate; CI=confidence interval; ED=emergency department; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; FEV1=forced expiratory volume in 1 second; IgE=immunoglobulin E; LS=least-squares; RR=rate ratio; SOC=standard of care.

EXPLORE EFFICACY

In an overall population, TEZSPIRE showed significant exacerbation reductions versus placebo (PATHWAY 71%, NAVIGATOR 56%, P<0.001; primary endpoint) and a 230 mL improvement in lung function versus baseline (NAVIGATOR; secondary endpoint).6† In a post hoc analysis of patients with EOS ≥300 cells/μL with positive aeroallergen testing,* the following data were observed with TEZSPIRE10:

  • 79% reduction in exacerbations from baseline‡§ (TEZSPIRE + SOC [n=181]; baseline 2.96 vs EOT 0.63)
  • 93% reduction in exacerbations requiring hospitalizations, urgent care, or ED visits from baseline‡II (TEZSPIRE + SOC [n=181]; baseline 0.44 vs EOT 0.03)
  • 370 mL improvement in FEV1 from baseline (TEZSPIRE + SOC [n=171])

Results are descriptive only. Definitive conclusions cannot be made.

*Allergic status as defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.10

†PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% CI: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% CI: 0.37-0.53).6

‡Baseline is defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT is defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).10

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.94 and EOT 1.88 (n=179; 36% reduction from baseline).10‡

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.47 and EOT 0.23 (n=179; 51% reduction from baseline).10‡

Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 160 mL (n=165); LS mean difference between groups 210 mL (95% CI: 120-290).10

AAER=annualized asthma exacerbation rate; CI=confidence interval; ED=emergency department; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; FEV1=forced expiratory volume in 1 second; IgE=immunoglobulin E; LS=least-squares; RR=rate ratio; SOC=standard of care.

EXPLORE EFFICACY

In an overall population, TEZSPIRE showed significant exacerbation reductions versus placebo (PATHWAY 71%, NAVIGATOR 56%, P<0.001; primary endpoint) and a 230 mL improvement in lung function versus baseline (NAVIGATOR; secondary endpoint).6† In a post hoc analysis of patients with EOS ≥450 cells/μL with positive aeroallergen testing,* the following data were observed with TEZSPIRE9:

  • 82% reduction in exacerbations from baseline‡§ (TEZSPIRE + SOC [n=98]; baseline 2.96 vs EOT 0.52)
  • 92% reduction in exacerbations requiring hospitalizations, urgent care, or ED visits from baseline‡II (TEZSPIRE + SOC [n=98]; baseline 0.38 vs EOT 0.03)
  • 440 mL improvement in FEV1 from baseline (TEZSPIRE + SOC [n=98])

Results are descriptive only. Definitive conclusions cannot be made.

*Allergic status as defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.9

†PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% CI: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% CI: 0.37-0.53).6

‡Baseline is defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT is defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).9

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 3.10 and EOT 2.20 (n=106; 29% reduction from baseline).9‡

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.56 and EOT 0.29 (n=106; 48% reduction from baseline).9‡

Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 200 mL (n=106); LS mean difference between groups 240 mL (95% CI: 130-350).9

AAER=annualized asthma exacerbation rate; CI=confidence interval; ED=emergency department; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; FEV1=forced expiratory volume in 1 second; IgE=immunoglobulin E; LS=least-squares; RR=rate ratio; SOC=standard of care.

EXPLORE EFFICACY

RAPID RESPONSE: 70% of lung function was achieved at 2 weeks.6,11 Statistical significance was established at end of treatment.

SUSTAINED RESPONSE: Better breathing was demonstrated by a statistically significant improvement compared to placebo in FEV1 at 52 weeks6,12*†

  • 230 mL improvement from baseline with TEZSPIRE + SOC (n=528)6,12

TEZSPIRE is not a rescue medication.

*Statistical significance for FEV1 improvement was established at end of treatment. Week 2 results were descriptive only.6,11,12

†Data are means (95% CI). Results from the NAVIGATOR study.11

CI=confidence interval; FEV1=forced expiratory volume in 1 second; SOC=standard of care.

EXPLORE EFFICACY

Yes. There are exacerbation reduction data by key trigger types and seasons vs placebo.13,14

EXPLORE EFFICACY 

Patients on TEZSPIRE reported significant improvements in asthma symptom control (ACQ-6) and quality of life (AQLQ(S)+12) compared with placebo.12

ACQ-6=Asthma Control Questionnaire-6; AQLQ(S)+12=Asthma Quality of Life Questionnaire with standardized activities for ages 12 and older.

EXPLORE EFFICACY 

The most common adverse reactions (incidence ≥3% and more common than placebo) reported with TEZSPIRE were pharyngitis* (4% vs 3% with placebo), arthralgia (4% vs 3% with placebo), and back pain (4% vs 3% with placebo).6†

*Pharyngitis (including pharyngitis, pharyngitis bacterial, pharyngitis streptococcal, and viral pharyngitis).

†This list does not contain all the possible side effects of TEZSPIRE.

SEE PROFILE 

Use the TEZSPIRE Clinical Data Tool to gain insights from the TEZSPIRE clinical trials. Explore patient types by selecting different EOS levels and allergic status.

EOS=eosinophils.

LAUNCH CLINICAL DATA TOOL

TEZSPIRE is administered subcutaneously every 4 weeks from either a pre-filled syringe or a pre-filled pen.6

The TEZSPIRE pre-filled syringe is administered by a healthcare provider, and the pre-filled pen can be administered by patients/caregivers or healthcare providers.6

LEARN MORE ABOUT DOSING & ADMINISTRATION

No. There’s a standard recommended dosage for all patients6:

  • 210 mg administered subcutaneously every 4 weeks

There is no loading dose, variation in dosing schedule, or dose adjustments based on weight or biomarker level.6

LEARN MORE ABOUT DOSING & ADMINISTRATION

If a dose is missed, administer the dose as soon as possible. After, your patient can continue (resume) dosing on the usual day of administration. If the next dose is already due, then administer as planned.6

LEARN MORE ABOUT DOSING & ADMINISTRATION

Instructions for use will vary based on your preferred method of administration–pre-filled syringe or pre-filled pen. Find both in the Instructions for Use.

TEZSPIRE Together offers a variety of support to help you and your patients get started and continue throughout their treatment journey.

Our co-pay program helps eligible commercially insured patients reduce out-of-pocket costs. Patients may pay as little as $0 for each dose of medication.* The program also covers up to $100 per month of patient costs for in-office administration.†

TEZSPIRE Together provides an online healthcare provider portal to help you with electronic benefits verifications, prior authorizations, and appeals support.

*For commercially insured patients only. Eligibility criteria and program maximums apply. See TEZSPIRE.com for full program details.

†Patients who are residents of Massachusetts or Rhode Island are not eligible for injection administration support.

LEARN MORE ABOUT SUPPORT & RESOURCES

TEZSPIRE Together offers a variety of resources throughout the treatment journey, including help with:

  • Electronic benefits verifications
  • Prior authorizations
  • Appeals

Our co-pay program helps eligible commercially insured patients reduce out-of-pocket costs. Patients may pay as little as $0 for each dose of medication.* The program also covers up to $100 per month of patient costs for in-office administration.†

*For commercially insured patients only. Eligibility criteria and program maximums apply. See TEZSPIRE.com for full program details.

†Patients who are residents of Massachusetts or Rhode Island are not eligible for injection administration support.

LEARN MORE ABOUT SUPPORT & RESOURCES

Patients enrolled in the TEZSPIRE Together Co-Pay Program were nearly 2x more likely to fill their prescription compared to those who did not enroll.15*

*New commercially insured patients prescribed TEZSPIRE by an allergist, pulmonologist, PCP, or other HCP between March 1, 2023 and March 1, 2024, while enrolled in the TEZSPIRE Together Co-Pay Program.15

HCP=healthcare professional; PCP=primary care physician.

LEARN ABOUT OUR CO-PAY PROGRAM

There are 2 ways to enroll:

Portal Registration

Online

Via the TEZSPIRE Together HCP Portal

Fax Registration

Fax

Download and print the enrollment form, then fax the completed form to 1-888-388-6016

HELP GET PATIENTS STARTED

Important Safety Information

Collapse

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Acute Asthma Symptoms or Deteriorating Disease

TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Live Attenuated Vaccines

The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 3%) are:

  • Asthma: pharyngitis, arthralgia, and back pain.
  • Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia

USE IN SPECIFIC POPULATIONS

There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATION

TEZSPIRE is indicated for:

  • the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus
  • the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)

Please see full Prescribing Information, including
Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products Opens new window. Opens new window

Important Safety Information

 +

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2.  Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-105253, AstraZeneca Pharmaceuticals LP. 7. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.

Reference: 1. Data on File. US-105253, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.

References: 1. Price D, Dale P, Elder E, Chapman KR. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. J Asthma. 2014;51(2):127-135. 2. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 3. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 4. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 5. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 8. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.

References: 1. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915-932. 6. Data on File. REF-263922, AstraZeneca Pharmaceuticals LP. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 8. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 9. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 10. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 11. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.

References: 1. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 7. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 11. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 10. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 12. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 13. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 14. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 15. Data on File. US-98281, AstraZeneca Pharmaceuticals LP.

References: 1. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Brace yourselves: the biggest week for asthma attacks is coming. Asthma and Allergy Foundation of America. Published August 25, 2022. Accessed August 5, 2025. https://community.aafa.org/blog/September-Asthma-Peak-brace-yourselves-the-biggest-week-for-asthma-attacks-is-coming. 7. Protect your child against the September epidemic. National Jewish Health. Accessed August 5, 2025. https://www.nationaljewish.org/conditions/health-information/multimedia/living-with-asthma/protect-your-child-against-the-september-epidemic. 8. Sheehan WJ, Patel SJ, Margolis RH, et al. Pediatric asthma exacerbations during the COVID-19 pandemic: absence of the typical fall seasonal spike in Washington, DC. J Allergy Clin Immunol Pract. 2021;9(5):2073-2076. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5.

References: 1. van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy. 2017;72(2):282-290. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-292218, AstraZeneca Pharmaceuticals LP. 3. Pfaar O, Han JK, Desrosiers M, et al. Onset of action of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study. Presented at: European Rhinologic Society (ERS) 2025 Congress; June 22-25, 2025; Budapest, Hungary. 4. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps [Appendix]. N Engl J Med. 2025;392(12):1178-1188. 5. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178-1188. 6. Chowdhury NI, Mace JC, Bodner TE, et al. Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(12):1149-1155. 7. Data on File. REF-287771, AstraZeneca Pharmaceuticals LP. 8. Data on File. WAYPOINT Clinical study report. Tezepelumab D5242C00001; January 23, 2025.

References: 1. Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149(5):1491-1503. 2. Peters A, Zhao X, Near AM, et al. Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps. Adv Ther. 2025;42(4):1783-1799. 3. Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725-739. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. Ha J-G, Cho H-J. Unraveling the role of epithelial cells in the development of chronic rhinosinusitis. Int J Mol Sci. 2023;24(18):14229. 7. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 8. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56.

This product information is intended for US Healthcare Professionals only.

TEZSPIRE is a registered trademark of Amgen Inc.
and AstraZeneca.
©2026 AstraZeneca. All rights reserved. US-106943; US-110429 Last Updated 7/26US-99228; US-106278; US-106943 Last Updated 3/26